Documentos clave

Ver Toda la documentación

I0160

Imipenem monohydrate

Name: Imipenem monohydrate
Brand: SIGMA

≥98% (HPLC), B-lactam antibiotic, powder

Sinónimos:

(5R,6S)-6-[(1R)-1-Hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate, Primaxin monohydrate, Tienam monohydrate

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):

C₁₂H₁₇N₃O₄S · H₂O

Número CAS:

74431-23-5

Peso molecular:

317.36

NACRES:

NA.77

PubChem Substance ID:

329815301

UNSPSC Code:

12352200

EC Number:

264-734-5

MDL number:

MFCD09753321

Assay:

≥98% (HPLC)

Form:

powder

Servicio técnico

¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.

Permítanos ayudarle

Propiedades

Nombre del producto

Imipenem monohydrate, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

antibiotic activity spectrum

mycobacteria

mode of action

cell wall synthesis | interferes

originator

Merck & Co., Inc., Kenilworth, NJ, U.S.

storage temp.

−20°C

SMILES string

O.C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O

InChI

1S/C12H17N3O4S.H2O/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17;/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19);1H2/t6-,7-,9-;/m1./s1

InChI key

GSOSVVULSKVSLQ-JJVRHELESA-N

Descripción

General description

Chemical structure: β-lactam

Application

Imipenem monohydrate has been used to determine the resistance profiles of Pseudomonas aeruginosa isolates. It has also been used in susceptibility testing against Acinetobacter baumannii.

Biochem/physiol Actions

Imipenem is found effective against gram positive and negative aerobes and anaerobes. Imipenem is often combined with cilastatin, to inhibit its metabolism in kidney.

Imipenem monohydrate is a broad spectrum B-lactam antibiotic.

Imipenem monohydrate is a broad spectrum B-lactam antibiotic. It is a member of the carbapenem class of "magic bullet" antibiotics for severe infections.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under

Clase de almacenamiento

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Could plazomicin alone or in combination be a therapeutical option against carbapenem-resistant Acinetobacter baumannii?

Garcia Salguero C, et al.

Antimicrobial agents and chemotherapy, AAC-00873 (2015)

A 10 year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China.

Qiwen Yang et al.

Journal of medical microbiology, 62(Pt 9), 1343-1349 (2013-06-07)

The objective of this study was to investigate the susceptibility of hospital-associated (HA) and community-associated (CA) Escherichia coli and Klebsiella pneumoniae isolated from patients with intra-abdominal infections (IAIs) in China. From 2002 to 2011, the minimum inhibitory concentrations (MICs) of

Antibiotic and chemotherapy e-book, 234-234 (2010)

Ver todos los artículos relacionados